Skip to main content
NewslettersWatchlist

Chemomab Therapeutics Ltd ADR(CMMB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.8200
Day High0.8800
Open:0.8800
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
AllPennyStocks.com
Biotech Shares Massively Bid Up Before Opening Bell
PR Newswire
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PR Newswire
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
PR Newswire
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
PR Newswire
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023
PR Newswire
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023
PR Newswire
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
PR Newswire
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
PR Newswire
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
PR Newswire
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference
PR Newswire
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
PR Newswire
Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update
PR Newswire
Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023
Baystreet
First Quarter Ends with Canadian Payroll Numbers
PR Newswire
Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update
PR Newswire
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
PR Newswire
Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis
PR Newswire
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy
PR Newswire
Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
PR Newswire
Chemomab Presents Preclinical Data at AASLD The Liver Meeting® 2022 Highlighting Key Role of CCL24 in Pathophysiology of Primary Sclerosing Cholangitis
PR Newswire
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
PR Newswire
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
PR Newswire
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update
PR Newswire
Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis
Globe NewsWire
Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

Profile

Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV, Israel.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.